Nicotine-Induced Structural Plasticity in Mesencephalic Dopaminergic Neurons Is Mediated by Dopamine D3 Receptors and Akt-mTORC1 Signaling

Ginetta Collo, Federica Bono, Laura Cavalleri, Laura Plebani, Stefania Mitola, Emilio Merlo Pich, Mark J. Millan, Michele Zoli, Uwe Maskos, PierFranco Spano, and Cristina Missale

Department of Molecular and Translational Medicine (G.C., F.B., L.C., L.P., S.M., P.F.S., C.M.) and Woman Health Center-Camillo Golgi Foundation (G.C., F.B., L.C., P.F.S., C.M.), University of Brescia, Brescia, Italy; Neuroscience Pharmaceutical Division, Hoffman-La Roche, Basel, Switzerland (E.M.P.); Division of Psychopharmacology, Institut de Recherches Servier, Croissy-Sur-Seine, France (M.J.M.); Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy (M.Z.); and Unité de Neurobiologie Intégrative des Systèmes Cholinergiques, Centre National de la Recherche Scientifique, Unité de Recherche Associée 2182, Institut Pasteur, Paris, France (U.M.)

Received January 22, 2013; accepted March 19, 2013

ABSTRACT

Although long-term exposure to nicotine is highly addictive, one beneficial consequence of chronic tobacco use is a reduced risk for Parkinson’s disease. Of interest, these effects both reflect structural and functional plasticity of brain circuits controlling reward and motor behavior and, specifically, recruitment of nicotinic acetylcholine receptors (nAChR) in mesencephalic dopaminergic neurons. Because the underlying cellular mechanisms are poorly understood, we addressed this issue with use of primary cultures of mouse mesencephalic dopaminergic neurons. Exposure to nicotine (1–10 µM) for 72 hours in vitro increased dendritic arborization and soma size in primary cultures. These effects were blocked by mecaminium and dihydro-β-erythroidine, but not methyllycaconitine. The involvement of α4β2 nAChR was supported by the lack of nicotine-induced structural remodeling in neurons from α4 null mutant mice (KO). Challenge with nicotine triggered phosphorylation of the extracellular signal-regulated kinase (ERK) and the thymoma viral proto-oncogene (Akt), followed by activation of the mammalian target of rapamycin complex 1 (mTORC1)-dependent p70 ribosomal S6 protein kinase. Upstream pathway blockade using the phosphatidylinositol 3-kinase inhibitor LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one hydrochloride] resulted in suppression of nicotine-induced phosphorylations and structural plasticity. These effects were dependent on functional DA D3 receptor (D3R), because nicotine was inactive both in cultures from D3R KO mice and after pharmacologic blockade with D3R antagonist trans-N-4-2-[6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl]ethylcyclohexyl-4-quinolinecarboxamide (SB-277011-A) (50 nM). Finally, exposure to nicotine in utero (5 mg/kg/day for 5 days) resulted in increased soma area of DAergic neurons of newborn mice, effects not observed in D3 receptor null mutant mice. These findings indicate that nicotine-induced structural plasticity at mesencephalic dopaminergic neurons involves α4β2 nAChRs together with dopamine D3R-mediated recruitment of ERK/Akt-mTORC1 signaling.

Introduction

Tobacco smoking is a pervasive habit that has been associated with pathologic addiction (Benowitz 1988) and reduced risk for Parkinson’s disease (PD) (Grandinetti et al., 1994; Wirdefeldt et al., 2011). Of interest, in both conditions, a critical substrate was recognized to be the DAergic system, involving neurons located in the ventral tegmental area (VTA) (Corrigall et al., 1994) and the substantia nigra (SN) (Quik et al., 2006), respectively. Although an impressive amount of neuropharmacological...
studies was dedicated to the effect of nicotine on the mesencephalic DAergic system, comparatively little research has focused on morphologic remodeling and structural plasticity. Of interest, morphologic remodeling was found with other addictive drugs, including psychostimulants (Nestler et al., 1993; Mueller et al., 2006; Sarti et al., 2007). Using primary culture from mouse embryo, we recently showed that exposure to amphetamine and cocaine produced structural plasticity in vitro by increasing dendrite number, maximal dendrite length, and soma area of mesencephalic DAergic neurons (Collo et al., 2008, 2012). These effects were conditional on functional dopamine D3 receptor (D3R), a 7-transmembrane receptor (Missale et al., 1998) implicated in the reinforcing properties of psychostimulants and nicotine (Heidbreder et al., 2005; Le Foll et al., 2007). Of interest, similar structural plasticity was produced by D3R-preferential DAergic agonists (Van Kampen and Eckman, 2006; Collo et al., 2008), agents currently used for PD treatment (Joyce and Millan, 2007).

The evidence for neurotrophic effects of nicotine is not unprecedented. Nicotine exposure attenuates the damage produced by nigrostriatal pathway lesions and fosters regeneration of the DAergic system (Janson et al., 1988a,b; Quik et al., 2006). More recently, transcriptional profiling in VTA showed that nicotine regulates 47 genes involved in neuronal morphogenesis (Doura et al., 2010). Nicotine exerts its effects by binding to the nicotinic acetylcholine receptors (nAChRs), transmembrane pentameric oligomers consisting of different combinations of 9 a-subunits and 3 b-subunits (Changeux, 2010). In DAergic neurons, the major functional receptors are a4b2 nAChRs that play a primary role in controlling DA release, neuronal firing, and nicotine-induced behavior (Picciotto et al., 1998; Marubio et al., 2003; Changeux, 2010).

In this article, we investigated the structural remodeling effects of nicotine in mesencephalic DAergic neurons by studying the morphologic changes produced by nicotine in an established protocol of primary neuronal cultures from mouse embryo (Collo et al., 2008, 2012). Pharmacologic antagonists and neuronal cultures derived from mice carrying a nAChR subunit or D3R gene knockout (KO) mutation were used to dissect the critical components of structural plasticity produced by nicotine. Because a large body of evidence involves phosphorylation of extracellular signal-regulated kinase (ERK) and thymoma viral proto-oncogene (Akt) in dendrite outgrowth and soma size increase via activation of the mammalian target of rapamycin (mTOR) (Kwon et al., 2003; Jaworski et al., 2006), our current study focused on morphologic remodeling and neuronal cultures derived from mice carrying a nAChR subunit or D3R gene knockout (KO) mutation were used to delineate the role of these intracellular pathways. To confirm the relevance in vivo of these observations, we studied the morphologic effects of nicotine on the DAergic system of newborn mice exposed in utero at the same embryonic stage as the in vitro cultures.

Materials and Methods

Chemicals. (-)-Nicotine ditartrate, mecamylamine, dihydro-β-erythroidine (DHbE), methyllycaconitine (MLA), 7-hydroxy-N,N-di-propyl-2-aminotetralin (7-OH-DPAT), sulpiride, (R)-(+)-7-chloro-5-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390), rapamycin, 2-(4-morpholinyl)-8-phenyl-1-benzopyran-4-one hydrochloride (LY294002), and 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98059) was purchased from Tocris Bioscience (Bristol, UK); brain-derived neurotrophic factor (BDNF) was from Alomone Laboratories Ltd. (Jerusalem, Israel); and SB-277011-A was a gift from C. Heidbreder, GlaxoSmithKline (Verona, Italy). Nicotine, mecamylamine, DHbE, MLA, 7-OH-DPAT, SCH23390, and BDNF were dissolved in water; SB-277011-A, rapamycin, PD98059, and LY294002 were dissolved in dimethylsulfoxide (>1:3000 final dilution), while sulpiride was dissolved in ethanol (1:2000 final dilution), all as recommended by producer. For each control treatment, the vehicle was prepared with the respective dilution of dimethylsulfoxide or ethanol.

Animals. CD1 mice were obtained from Charles River Laboratories (Calco, Italy). The following knockout mice were used: mice genetically deprived of dopamine D3R (D3KO) from the Jackson Laboratory (Bar Harbor, ME) (B6.129S4-Drd3tm1Dac/J) (Acili et al., 1996) and mice genetically deprived of a4 subunit of nAChR (a4KO) (Marubio et al., 2003). As control, C57BL/6J mice were used. Breeding of all mice was performed to achieve timed pregnancy with the accuracy of ±0.5 days. The embryonic day (E) was determined by considering the day of insemination (determined by vaginal plug) as day E0.5. Animal care was in accordance with the European Communities Council Directive of November 24, 1986 (86/609/EEC), and in line with Italian law.

Primary Mesencephalic Cultures. Primary mesencephalic cultures were prepared as described in Collo et al. (2008). In brief, ventral mesencephalon tissues were dissected from E12.5 mouse embryos (sex unknown) and collected in ice-cold Hanks’ buffered salt solution (EuroClone, Milan, Italy). Tissues were transferred in Accumax (Sigma-Aldrich, St. Louis, MO), mechanically dissociated at room temperature, and resuspended in Neurobasal medium (Gibco (Invitrogen), Carlsbad, CA) containing 2 mM glutamate (EuroClone) and B27 supplement (Gibco (Invitrogen)). Cells were counted, seeded on poly-D-lysine/laminin- (Sigma-Aldrich) coated coverslides (5 × 104 cells/ml) or 12-well plates (5 × 105 cells/ml), and cultured at 37°C in a humidified atmosphere of 5% CO2 and 95% air. No fetal bovine serum was added to the cultures; 50% of the medium was changed every two days until treatment. Under these conditions, the cultures contained >99.5% neurons and <0.5% astrocytes, as assessed by microtubule-associated protein 2 and glial fibrillary acidic protein immunostaining, respectively (unpublished data). Pharmacological treatments were conducted in vitro after 5 days from seeding, time required for primary culture stabilization.

In Vivo Prenatal Nicotine Treatment. Pregnant D3KO and wild-type mice were individually housed in a climate-controlled room on a 12/12-hour light/dark cycle with ad libitum access to food and water. Treatments were performed during the light period (9:00 AM – 6:00 PM). All mice were weighed daily starting at day 10. At day 12.5, pregnant mice weighing 25–30 g were administered intraperitoneally with two daily doses of 5 mg/kg nicotine or saline as described by Vezina et al. (2007). Treatments were repeated for 5 days, from E12.5 through E17. After each injection, animals were placed for 30 minutes in a clean cage and inspected for locomotor activity. After delivery, P1 newborn mice (sex unknown) were sacrificed, and the brains were removed and processed for immunohistochemistry.

Immunocytochemistry and Immunofluorescence in Primary Cultures. Immunocytochemistry and immunofluorescence were performed as described in Collo et al. (2012). In brief, for immunocytochemistry, mesencephalic neurons were fixed in phosphate-buffered saline (PBS) containing 3% paraformaldehyde and 3% sucrose (both Sigma-Aldrich); blocked in PBS containing 0.3% Triton (Promega, Madison, WI); 1% normal goat serum (Jackson ImmunoResearch, West Grove, PA), and 5% bovine serum albumin (BSA; Sigma-Aldrich); and incubated overnight at 4°C with a rabbit polyclonal antibody to tyrosine hydroxylase (TH) antibody (1:1500; Santa Cruz Biotechnology, Santa Cruz, CA), followed by a biotinylated goat anti-rabbit antibody (Jackson ImmunoResearch; 30 minutes at room temperature) and a final incubation with avidin-biotinylated horseradish peroxidase complex (ABC; Vector Laboratories, Burlingame, CA). Color development was achieved by addition of 3,3′-diaminobenzidine (Sigma-Aldrich) for 45 seconds. To study the expression of phosphorylated ERK (p-ERK1/2) or Akt (p-Akt Thr308) in dopaminergic neurons,
mesencephalic cultures were fixed with methanol and incubated with a rabbit polyclonal antibody anti-TH (1:800; Santa Cruz Biotechnology) or a mouse monoclonal antibody anti-TH (1:700; Millipore, Billerica, MA), together with a mouse monoclonal antibody to p-ERK1/2 (1:400; Cell Signaling Technology), respectively. To investigate the expression of Thr-389 phosphorylated p70 ribosomal S6 protein kinase (p-p70S6K), a mouse monoclonal antibody anti- p-p70S6K (1:500; Cell Signaling Technology) was used together with the rabbit polyclonal antibody anti-TH. Alexa Fluor 488- and Cy3-conjugated secondary antibodies (Jackson ImmunoResearch) were used. As negative control, cultured neurons were incubated with the secondary antibodies only. Each experiment was repeated three times, and all dopaminergic neurons present in two coverslides for each treatment condition were assessed. Immunofluorescences for p-ERK1/2 and p-Akt(Thr308) were visualized using an Olympus IX51 microscope (Hamburg, Germany), and TH- immunoactivity (IR) neurons immunostained for p-p70S6K were analyzed using a Zeiss LSM 510 Meta confocal microscope equipped with Plan-Apochromat 63×/1.4 numerical aperture oil objective and LSM 510 Meta Software, version 3.5 (Carl Zeiss AG, Oberkochen, Germany). Confocal digital images were further examined using the Axio Vision Release, version 4.8.2, software (Carl Zeiss AG).

**Immunohistochemistry of Brain Sections.** Newborn mice were sacrificed at P1, and brain was removed, fixed overnight in PBS 4% paraformaldehyde, cryoprotected in 20% sucrose, and rapidly frozen by immersion in isopentane on dry ice. For each brain, a complete set of coronal sections was cut through the SN and VTA at 30 μm. Sections were mounted on slides, blocked, and permeabilized with PBS, 5% BSA (Sigma-Aldrich), and 0.1% Triton (Sigma-Aldrich) for 30 minutes at room temperature. They were incubated with the rabbit anti-TH antibody (1:500; Santa Cruz Biotechnology) diluted in PBS and 1% BSA overnight at 4°C. Then, they were washed and incubated with a biotinylated goat anti-rabbit antibody (Jackson ImmunoResearch) diluted in PBS and 1% BSA for 30 minutes at room temperature, followed by the ABCComplex and development with 3,3’-diaminobenzidine (DAB).

**Computer-Assisted Morphologic Analysis.** Digital images from primary neuronal cultures or mesencephalic brain tissues were acquired with an Olympus IX51 microscope connected to an Olympus digital camera and a PC. Morphometric measurements were performed by a blinded examiner on digitized images using Image-Pro Plus software (Media Cybernetics, Bethesda, MD). For in vitro primary neuronal culture, the morphologic indicators of structural plasticity were (i) the maximal dendrite length, (ii) the number of primary dendrites, and (iii) the soma area (Schmidt et al., 1996). Maximal dendrite length was defined as the distance from the soma (bliolock base) to the tip of the longest dendrite for each neuron; dendrites shorter than 20 μm were excluded from the analysis. Primary dendrites were defined as those directly stemming from the soma. Soma area was assessed by measuring the surface (μm²) included by the external perimeter drawn on the cell membrane of neurons identified by TH-IR staining. Two coverslides per treatment group were examined to obtain measurements from at least 30 neurons. For ex vivo studies, computer-assisted morphometry was performed as described in Collo et al. (2012). The effects of nicotine on newborn mice were assessed by measuring in each brain the soma area of 90–120 dopaminergic neurons at various rostrocaudal levels of SN and VTA, respectively. The same rostrocaudal levels were considered in each treatment group to keep anatomic variance primarily controlled. In a typical experiment, eight newborn mice from three different mothers per group were included. The soma area of dopaminergic neurons on histologic preparations was measured as described for TH-IR primary neuronal cultures.

**Western Blotting.** Western blotting was performed at different time points (1–10 minutes) after challenge with nicotine (10 μM) and/or after pretreatments with either D3R antagonist ST-277011-A (50 nM) or phosphatidylinositol-3-kinase (PI3K) antagonist LY294002 (10 μM). For studies in D3KO and singenic wild-type mice, challenges were produced with nicotine (10 μM) and 7-OH-DPAT (50 nM). Mesencephalic cultures were washed with ice-cold PBS and lysed in a buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% Igepal, 1 mM p- phosphotidanesulphonyl fluoride, and complete protease inhibitors (Roche Diagnostics, Mannheim, Germany) for 10 minutes in ice. Neurons were homogenized with a probe-type sonicator on ice and centrifuged at 13,000g for 10 minutes at 4°C. The protein concentration was measured using a DC-protein assay (Bio-Rad, Hercules, CA). Twenty micrograms of total proteins were resolved by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and blotted onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore). Membranes were blocked in Tris-buffered saline/Tween 20 (TBST; 25 mM Tris base, 137 mM NaCl, 2.7 mM KCl and 0.1% Tween-20, pH 7.6) and 5% dry milk and incubated overnight with the primary antibody diluted in 5% BSA in TBST. The primary antibodies used were anti-p-ERK1/2 (1:1000) and anti-ERK1/2 (1:1000) mouse monoclonal antibodies (both from Santa Cruz Biotechnology); anti-p-Akt(Thr308) (1:2000) rabbit polyclonal antibody; anti-Akt (1:1000) rabbit polyclonal antibody; anti-p-p70S6K (1:2000) and anti-p70S6K (1:2000) mouse monoclonal antibodies (all from Cell Signaling Technology); anti-TH (1:1000) rabbit polyclonal antibody (Millipore); and anti-a-Tubulin (1:20000) mouse monoclonal antibody (Sigma-Aldrich). In a typical experiment, the same membrane was processed in the following order: incubation with anti-p-ERK1/2 antibody, stripping with the Re-Blot Plus Strong Solution (Millipore), incubation with anti-TH antibody, incubation with anti-p-Akt antibody, stripping with the Re-Blot Plus Strong Solution (Millipore), and incubation with anti-α-Tubulin antibody. An equivalent protocol was performed for p-Akt and p-p70S6K blotting. After the incubation with primary antibodies, blots were washed in TBST, incubated with appropriate horseradish peroxidase–conjugated secondary antibodies (goat anti-rabbit or goat anti-mouse; Santa Cruz Biotechnology), and developed using a chemiluminescent substrate (ECL, LiteAblot Extend; EuroClone). Specific bands were analyzed by densitometric scanning of exposed film using Gel-pro analyzer software (Media Cybernetics). In each experiment, the specific signal of p-ERK1/2, p-Akt, and p-p70S6K proteins was normalized to the corresponding ERK1/2, Akt, or p70S6K signals, respectively, and then to the level of TH and α-Tubulin measured in the same preparation.

**Statistical Analysis.** Data were expressed as mean ± S.E.M. if not stated otherwise. Significant differences from control conditions were determined using either one-way or two-way analysis of variance, followed by a posteriori Bonferroni’s test for multiple comparisons provided by GraphPad Prism, version 4.0 for Windows (GraphPad Software, San Diego, CA).

**Results.**

**Nicotine-Induced Structural Plasticity in Primary Cultures of Mesencephalic DAergic Neurons.** Mesencephalic DAergic neurons were visualized using a TH antibody as shown in Fig. 1, A and B. The time- and dose-dependency of nicotine effects on structural plasticity measured as maximal dendrite length, number of primary dendrites, and cell body size are shown in Fig. 1, C–E. Various doses of nicotine (0.1, 1, and 10 μM) or vehicle were used, and their effects on neuronal cultures were seen at two different time points: 24 hours and 72 hours. The maximal length of dendrites showed a significant treatment effect \[F(3,232) = 54.32; P < 0.0001\], with significant difference from vehicle already at 1 μM nicotine and stronger effect at 10 μM nicotine (Bonferroni’s test \(P < 0.001\), versus vehicle). This effect was more marked at 72 hours, as indicated by the significant time effect \[F(1,232) = 9.28; P < 0.001\], while the treatment \(\times\) time interaction was not significant (Fig. 1C). The analysis of number of primary dendrites indicated a dose-related treatment effect...
[\(F(3,344)=141.7, P < 0.0001\)], with significant differences between each dose (Bonferroni’s test \(P < 0.001\)) and a significant time effect \([F(1,344) = 17.53; P < 0.0001]\) with the strongest signal at 72 hours (Bonferroni’s test \(P < 0.01\)).

Again, the treatment \(\times\) time interaction was not significant. The analysis of the cell soma area showed significant treatment effect \([F(3,232)=6.19; P < 0.0005]\) and time effect \([F(1,232)=57.01; P < 0.0001]\), with a treatment \(\times\) time interaction that was highly significant \([F(1,3) = 7.20; P < 0.0001]\). Post-hoc analysis showed that lack of effects at 24 hours versus baseline was associated with a strong growth at 72 hours, an effect that showed clear dose-dependency (Fig. 1E). In one independent series of experiments, when the dose of 10 \(\mu M\) nicotine was incubated for 10 minutes, 1 hour, 6 hours, 12 hours, 24 hours, and 72 hours, significant difference from vehicle of dendrite length, number, and soma area were observed starting at 12 hours, progressively increasing with a peak at 72 hours (unpublished data). On the basis of these observations, the nicotine dose of 10 \(\mu M\) and an incubation time of 72 hours were chosen for further studies.

Nicotine-Induced Structural Plasticity Depends on \(\alpha 4\beta 2^*\) nAChRs: Pharmacological and KO Mouse Studies. The involvement of nAChRs in nicotine-induced structural plasticity of mesencephalic DAergic neurons was tested in independent experiments after pretreatments with the nonselective nAChR antagonist mecamylamine (MEC), the selective \(\beta 2^*\) nAChR antagonist DH\(\beta E\), and the selective \(\alpha 7\) nAChR antagonist MLA (Fig. 2, A–C). The maximal dendrite length showed a significant treatment effect \([F(7,232) = 17.58; P < 0.0001]\), with nicotine producing a significant increase (Bonferroni’s test \(P < 0.001\)), and this effect was significantly attenuated by MEC or DH\(\beta E\) (Bonferroni’s test \(P < 0.01\)), but not by MLA; incubation with nAChR antagonists alone (i.e., when vehicle was added instead of nicotine) showed no difference from vehicle (Fig. 2A). Similar significant effects of treatment were observed for the number of primary dendrites \([F(7,471) = 9.69; P < 0.0001]\) (Fig. 2B), and for the soma area \([F(7,392) = 12.66; P < 0.0001]\) (Fig. 2C), the increase produced by nicotine (Bonferroni’s test \(P < 0.001\)) was significantly attenuated by MEC or DH\(\beta E\) (Bonferroni’s test \(P < 0.01\)) but not by MLA, whereas no difference was observed when the nAChR antagonists were given alone. Overall, these data indicate the involvement of \(\beta 2^*\) nAChR and excluded the involvement of \(\alpha 7^*\) nAChR.

Because the most common \(\beta 2^*\) nAChR expressed in DAergic neurons is the \(\alpha 4\beta 2^*\) nAChR (Champtiaux et al., 2003; Zhao-Shea et al., 2011), we extended these observations with use of cultures of mesencephalic neurons obtained from \(\alpha 4\) nAChR KO (\(\alpha 4\)KO) mice. Structural plasticity was tested by adding nicotine (10 \(\mu M\)), 7-OH-DPAT (5 nM), and BDNF (10 ng/ml) to the incubation media 72 hours before morphologic assessment. The D3R agonist 7-OH-DPAT (5 nM) was included because we previously showed a reliable neurotrophic-like effect in the same mesencephalic preparation (Collo et al., 2008), whereas BDNF is a well-known neurotrophic factor for DAergic neurons (Hyman et al., 1991). In this experiment, cultures from \(\alpha 4\)KO mice were compared with cultures from wild-type mice. Maximal dendrite length of DAergic neurons isolated from \(\alpha 4\)KO mouse embryos was significantly increased by BDNF and by 7-OH-DPAT (Bonferroni’s test \(P < 0.001\)), but not by nicotine, at variance with what was obtained in wild-type mice that responded significantly to all treatments (Bonferroni’s test \(P < 0.01\) or \(P < 0.001\)) (Fig. 2D).

The number of primary dendrites in response to treatments was also significantly affected by the \(\alpha 4\)KO genotype (Fig. 2E). Cultures prepared from \(\alpha 4\)KO mice responded significantly to 7-OH-DPAT and BDNF (Bonferroni’s test \(P < 0.05\) or \(P < 0.01\)) but were not affected by nicotine, whereas in cultures...
prepared from wild-type mice, all treatments were effective (Bonferroni’s test $P < 0.05$; or $P < 0.01$). Similar results were obtained when measuring the soma areas (Fig. 2F).

Overall, this study indicates that neurons carrying $\alpha_4$ null mutation are still capable of responding to neurotrophic stimuli, but not to nicotine, indicating a critical role of the $\alpha_4\beta_2^*$ nAChR in the structural plasticity produced by nicotine.

Nicotine-Induced Structural Plasticity Depends on Dopaminergic D3R: Pharmacological and D3KO Mouse Studies. To test this hypothesis, the involvement of dopaminergic receptors in nicotine-induced structural plasticity of mesencephalic dopaminergic neurons was assessed using pretreatments with the D1R antagonist SCH23390 (1 $\mu$M), the D2/D3R antagonist sulpiride (5 $\mu$M), or the D3R antagonist SB-277011-A (50 nM) added to the cultures 20 minutes before nicotine (10 $\mu$M) and studied after 72 hours. The maximal dendrite length was significantly affected by the treatment [$F(7,279) = 13.29; P < 0.0001$], with the nicotine-induced increase (Bonferroni’s test $P < 0.001$) significantly attenuated by sulpiride (Bonferroni’s test $P < 0.01$) and by SB-277011-A (Bonferroni’s test $P < 0.001$), but not by SCH23390, whereas incubation with dopamine antagonists alone, when vehicle was added instead of nicotine, showed no difference (Fig. 3A). Analogous results were obtained by measuring the number of primary dendrites, with a significant treatment effect [$F(7,383) = 10.28; P < 0.0001$]; the nicotine-induced increase (Bonferroni’s test $P < 0.001$) was attenuated by sulpiride (Bonferroni’s test $P < 0.001$) or SB-277011-A (Bonferroni’s test $P < 0.001$), but not by SCH23390 (Fig. 3B). The soma area was also affected by the treatments [$F(7,399) = 9.79; P < 0.0001$] in the same way described for maximal dendrite length and number of primary dendrites (Fig. 3C). These data support a critical role for D3R in mediating the nicotine effects on dopaminergic neuron structure.

The critical role of D3 receptors suggested by these pharmacologic observations was confirmed using mesencephalic neurons obtained from D3KO mice and compared with primary neurons from singenic wild-type mice. Structural plasticity was assessed 72 hours after incubation with nicotine.
(10 μM), the D3R agonist 7-OH-DPAT (5 nM), the neurotrophic factor BDNF (10 ng/ml), or vehicle. Maximal dendrite length was significantly affected by genotype, showing that cultures prepared from wild-type mice responded significantly to nicotine, 7-OH-DPAT, or BDNF (Bonferroni's test $P < 0.001$), whereas cultures prepared from D3KO mice responded significantly only to BDNF (Bonferroni's test $P < 0.001$), but not to nicotine or 7-OH-DPAT (Fig. 3A). The number of primary dendrites and soma size were also significantly affected by genotype, showing that, in cultures prepared from wild-type mice, nicotine, BDNF, and 7-OH-DPAT increased the number of primary dendrites (Bonferroni's test $P < 0.001$), whereas cultures prepared from D3KO mice significantly responded only to BDNF (Bonferroni's test $P < 0.001$), but not to nicotine or 7-OH-DPAT (Fig. 3, B and C). Overall, this study indicates that neurons carrying a D3R null mutation are still capable of responding to neurotrophic stimuli conveyed by BDNF, but not to those of nicotine and 7-OH-DPAT effects, suggesting a necessary role for D3R in mediating nicotine effects.

Nicotine Exposure in Pregnant Mothers Produced Structural Plasticity in Mesencephalic Neurons of the Offspring: Lack of the Effects in D3KO Mice. The in vivo relevance of the nicotine-induced changes observed in cultured mesencephalic dopaminergic neurons dissected from the E12.5 mouse embryo was investigated by repeatedly exposing mouse embryos to nicotine while in utero from E12.5 through E17. Treatments were performed in both wild-type and D3KO pregnant mice, and effects on soma area were measured on the mesencephalon of newborns (Fig. 4, A and B). Two-way analysis of variance was used to assess the genotype × treatment effects and interactions. The analysis of soma area in the VTA showed a significant genotype effect [$F(1,28) = 33.23; P < 0.0001$], treatment effect [$F(1,28) = 25.86; P < 0.0001$], and interaction [$F(1,28) = 14.44; P < 0.005$], with post-hoc test showing effect of nicotine only in wild-type mice ($P < 0.001$) (Fig. 4C). Soma area in the SN showed a significant genotype effect [$F(1,28) = 29.42; P < 0.0001$], treatment effect [$F(1,28) = 19.50; P < 0.0005$], and interaction [$F(1,28) = 19.40; P < 0.001$], with post-hoc test showing effect of nicotine only in wild-type mice ($P < 0.001$) (Fig. 4D).

Nicotine-Induced Activation of the Intracellular ERK and Akt-mTOR Pathways in Primary Dopaminergic Neurons Is Mediated by D3R. The effect of nicotine on ERK1/2 phosphorylation was investigated by challenging...
Mesencephalic neurons in culture with 10 μM nicotine. Western blot analysis over time showed an increase of p-ERK1/2 \( [F(4,23) = 7.63; P < 0.001] \), with a significant peak activity versus vehicle at 2 minutes (Bonferroni's test \( P < 0.01 \)) (Fig. 5A). Incubation with SB-277011-A (50 nM) 20 minutes before challenge significantly attenuated the p-ERK1/2 peak increase \( [F(3,15) = 8.91; P < 0.005] \), providing evidence of D3R involvement. No effect on p-ERK1/2 was produced by SB-277011-A when tested alone (Fig. 5B). Moreover, 20 minutes pretreatment with the PI3K inhibitor LY294002 (10 μM) significantly antagonized the peak increase of p-ERK1/2 levels \( [F(3,27) = 12.41; P < 0.0001] \), whereas no effects on ERK1/2 phosphorylation were observed when LY294002 was tested alone (Fig. 5C). Similar results were obtained in parallel experiments using double-staining immunofluorescence aimed to localize the expression of p-ERK1/2 in dopaminergic neurons. Nicotine activated p-ERK in TH-IR neurons (Fig. 5, D–F), and its effect was blocked by pretreatment with either SB-277011-A (Fig. 5, G–I) or LY294002 (Fig. 5, M–O). In control experiments, incubation with either SB-277011-A (Fig. 5, J–L) or LY294002 (Fig. 5, P–R) alone did not affect p-ERK1/2 expression.

Mesencephalic neurons obtained from embryos of D3KO and singenic wild-type mice were processed in separated cultures in the same experiment. The effects of either nicotine (10 μM) or 7-OH-DPAT (50 nM) on ERK1/2 phosphorylation were investigated by Western blot analysis 2 minutes after treatment. Nicotine and 7-OH-DPAT significantly increased p-ERK1/2 in wild-type mice \( [F(2,24) = 5.68; P < 0.01] \) but not in D3KO mice, as indicated by the highly significant interaction \( [F(2,24) = 13.60; P < 0.0001] \) and genotype effect \( [F(1,24) = 46.40; P < 0.0001] \) obtained with two-way analysis of variance (Fig. 5S).

The effect of nicotine on Akt phosphorylation was investigated by challenging mesencephalic neurons with 10 μM nicotine. Western blot analysis showed a rapid increase in Akt phosphorylation \( [F(4,27) = 9.03; P < 0.0002] \), reaching the peak activity at 1 minute exposure (Bonferroni's test \( P < 0.01 \)) (Fig. 6A). Incubation with SB-277011-A (50 nM) 20 minutes before challenge significantly attenuated the increase of Akt phosphorylation produced by nicotine \( [F(3,19) = 8.40; P < 0.002] \) (Fig. 6B). Moreover, 20 minutes pretreatment with LY294002 (10 μM) antagonized the significant increase of p-Akt levels \( [F(3,19) = 7.91; P < 0.002] \) (Fig. 6C). Similar results were obtained in parallel experiments using double-staining immunofluorescence aimed to localize the expression of p-Akt in dopaminergic neurons. Nicotine activated p-Akt in TH-IR neurons (Fig. 6, D–F), whereas its effect was blocked by pretreatment with either SB-277011-A (Fig. 6, G–I) or LY294002 (Fig. 6, M–O). In control experiments, incubation with either SB-277011-A (Fig. 6, J–L) or LY294002 (Fig. 6, P–R) alone did not affect p-Akt expression. Mesencephalic neurons obtained from embryos of D3KO and singenic wild-type mice were processed in separated cultures in the same experiment. Increase of p-Akt was produced by nicotine and 7-OH-DPAT in cultures from wild-type mice but not in D3KO mice, as indicated by the highly significant interaction \( [F(2,24) = 15.73; P < 0.02] \) and genotype effect \( [F(1,24) = 26.10; P < 0.0001] \) obtained with two-way analysis of variance (Fig. 6S).

The effect of nicotine on p70S6K phosphorylation, one of the main substrates of the activated mammalian target of rapamycin complex 1 (mTORC1), was investigated by challenging mesencephalic neurons with 10 μM nicotine. Western blot analysis showed a delayed increase of p70S6K phosphorylation \( [F(4,21) = 8.00; P < 0.001] \) that reached the peak activity at 5 minutes exposure (Bonferroni's test \( P < 0.001 \)) (Fig. 7A). Incubation with SB-277011-A (50 nM) 20 minutes before challenge significantly attenuated the increase of p70S6K phosphorylation produced by nicotine \( [F(3,21) = 7.61; P < 0.002] \) (Fig. 7B). Moreover, 20 minutes pretreatment with LY294002 (10 μM) antagonized the increase of p-p70S6K levels \( [F(3,21) = 10.03; P < 0.0005] \) (Fig. 7C).

Information about colocalization of p-p70S6K-IR in TH-IR neurons after nicotine was obtained in parallel experiments using confocal microscopy (Fig. 7, D–L). Nicotine activated p-p70S6K-IR in TH-IR neurons (Fig. 7D). Confocal reconstructed TH-IR dendrites visualized with different angles confirmed the presence of p-p70S6K-IR and TH-IR in the same structures (Fig. 7, E and F). Of interest, p-p70S6K-IR and TH-IR showed only a partial overlap of IR, suggesting localization in different dendrite microdomains (Fig. 7, E and F). No p-p70S6K-IR was observed in TH-IR neurons and dendrites when the treatment was vehicle (Fig. 7, G and H) or following nicotine after 20 minutes pretreatment with SB-277011-A (Fig. 7, I and J) or LY294002 (Fig. 7, K and L), confirming the data obtained with Western blot.

Nicotine-Induced Structural Plasticity Is Blocked by Inhibition of the D3R Intracellular Signaling Pathways. The involvement of phosphokinases that mediate the activation of the ERK1/2, Akt, and mTORC1 intracellular pathways in determining nicotine-induced long term structural

Fig. 4. Effects of prenatal nicotine exposure on structural plasticity of dopaminergic neurons of wild-type and D3KO newborn mice. (A) Representative low-magnification photomicrograph of a coronal brain section of a P1 mouse exposed to daily treatment with nicotine intraperitoneally (5 mg/kg/die) in utero from E12.5 through E17. Sections were immunostained with anti-TH antibody to identify dopaminergic neurons in VTA and SN. (B) High magnification of TH-IR dopaminergic neurons from VTA, in which soma area was investigated. (C and D) Nicotine effects on the soma area of TH-IR neurons in the VTA and SN, respectively, of wild-type and D3KO mice. In all panels, values are represented as mean ± S.E.M. (**P < 0.001 versus saline; post-hoc Bonferroni's test). Scale bar: 60 μm.

![Image 36x499 to 286x729]
plasticity of mesencephalic dopaminergic neurons was tested in independent experiments. Nicotine (10 μM) was administered after pretreatments with the pharmacologic inhibitors LY294002 (10 μM), rapamycin (2 nM), or PD98059 (10 μM), which block phosphorylation of PI3K, mTORC1, and mitogen-activated protein kinase kinase (MEK), respectively. Three days later, maximal dendrite length showed a significant treatment effect, mostly because of a reliable increase produced by nicotine (Bonferroni’s test P < 0.001) that was attenuated in various experiments by pretreatment with either LY294002 (F(3,127) = 5.730; P < 0.0002; Bonferroni’s test P < 0.01) (Fig. 8A), rapamycin (F(3,159) = 8.71; P < 0.0001; Bonferroni’s test P < 0.01) (Fig. 8D), or PD98059 (F(3,123) = 9.10; P < 0.0001; Bonferroni’s test P < 0.01) (Fig. 8G).

Similar significant outcomes were observed for the number of primary dendrites; the enhancing effects of nicotine (Bonferroni’s test P < 0.01) were blocked by pretreatment with LY294002 (F(3,122) = 6.11; P < 0.001; Bonferroni’s test P < 0.01) (Fig. 8B), rapamycin (F(3,199) = 5.67; P < 0.001; Bonferroni’s test P < 0.05) (Fig. 8E), and PD98059 (F(3,119) = 5.66; P < 0.002;

Fig. 5. ERK1/2 phosphorylation activated by nicotine challenge in mesencephalic TH-IR neurons is prevented by D3R antagonist SB-277011-A and PI3K inhibitor LY294002 and is blocked in D3KO mice. (A) Representative time course of ERK1/2 phosphorylation induced by nicotine (10 μM) at 0, 1, 2, 5, and 10 minutes; cell lysates were processed for Western blot analysis that was performed using antibodies to detect pERK1/2, ERK1/2, TH, and tubulin levels; membranes were stripped and reprobed as described in Materials and Methods. Right panel, densitometric analysis of blots (n = 6) with specific levels of p-ERK1/2 normalized to the corresponding ERK1/2, TH, and tubulin levels. (B) Representative blot showing the effects of SB-277011-A (50 nM) added to the cultures 20 minutes before challenge with nicotine (10 μM) assessed after 2 minutes. Right panel, densitometric analysis of blots (n = 6) normalized as described. (C) Representative blot showing the effects of LY294002 (10 μM) added to the cultures 20 minutes before challenge with nicotine (10 μM) assessed after 2 minutes. Right panel, densitometric analysis of blots (n = 6) normalized as described. (D–R) Immunofluorescence microphotographs of TH-IR (D, G, J, M, and P), p-ERK-IR (E, H, K, N, and Q), and their colocalization (F, I, L, O, and R) in mesencephalic dopaminergic neurons 2 minutes after treatment with nicotine (D–F) and SB-277011-A (20 minutes), followed by nicotine (G–I), SB-277011-A alone (J–L), and LY294002, followed by nicotine (M–O) or LY294002 alone (P–R). Cell nuclei were stained with Hoechst. Scale bar: 20 μm. (S) Representative blot showing the effects of vehicle, nicotine, and 7-OH-DPAT on p-ERK1/2 in mesencephalic cultures from wild-type and D3KO mice. Right panel, densitometric analysis of blots (n = 4) normalized as described. V, vehicle; N, nicotine; SB, SB-277011-A; Ly, LY294002; 7OH, 7-OH-DPAT. Densitometric values were represented as percentage of vehicle or nicotine values as mean ± S.E.M. (***P < 0.001; **P < 0.01; *P < 0.05 versus vehicle; """"P < 0.001; ""P < 0.01 versus nicotine post-hoc Bonferroni test).
Bonferroni’s test $P < 0.05$ (Fig. 8H). The same pattern was observed by measuring the changes in TH-IR soma area, with increments produced by nicotine (Bonferroni’s test $P < 0.01$) that were antagonized by pretreatment with LY294002 $[F(3, 141) = 10.86; P < 0.0001; \text{Bonferroni’s test } P < 0.001]$ (Fig. 8C), rapamycin $[F(3, 159) = 7.23; P < 0.0001; \text{Bonferroni’s test } P < 0.01]$ (Fig. 8F), and PD98059 $[F(3, 137) = 6.01; P < 0.001; \text{Bonferroni’s test } P < 0.05]$ (Fig. 8I).

Overall, these data suggest that both the PI3K-Akt-mTORC1 and the PI3K-MEK-ERK signaling pathways are necessary to mediate the structural plasticity effects induced by nicotine in mesencephalic dopaminergic neurons.

**Discussion**

In the present study, we showed that prolonged exposure to nicotine produced structural plasticity in mesencephalic DAergic neurons of the mouse embryo by increasing soma area and dendrite arborisation via a mechanism dependent on D3R activation by engaging of ERK and Akt-mTOR signaling pathways. These findings support evidence of nicotine-dependent structural plasticity in the DAergic system (Janson et al., 1988a,b; Bunemann et al., 2000; Mudo et al., 2007) and clarify the role of specific intracellular pathways involved in growth and survival (Doura et al., 2010; Quik et al., 2012). In our work, nicotine produced structural changes in DAergic
neurons either when added to primary cultures obtained from the mesencephalon of E12.5 mouse embryos or when administered to pregnant mice at about the same stage of embryo development and studied in the VTA and SN of P1 offspring. In vitro studies in primary neurons were conducted using a validated protocol that generates almost pure neuronal cultures containing 5–7% dopaminergic neurons and less than 0.5% astrocytes (Collo et al., 2008). Nicotine produced a dose-dependent effect on maximal dendrite length and on the number of primary dendrites starting at the dose of 1 μM, levels observed in smokers and compatible with in vivo pharmacologic effects in mice (Changeux, 2010). In the present work, we chose to use the dose of 10 μM to maximize the pharmacological signal of the test. This effect was detectable at 12–24 hours and stabilized to the highest value at 72 hours of incubation. The delayed effect on neuronal soma was also observed after cocaine exposure (Collo et al., 2012), a phenomenon probably related to the soma geometry and/or to specific molecular substrates engaged in growth (Scheidenhelm et al., 2005; Russo et al., 2010). The involvement of α4β2* nAChR in mediating nicotine’s effects was supported by the blockade of dendrite and soma growth produced by the nonselective antagonist MEC and by the β2*-selective antagonist DHβE, whereas no effects were observed with the α7 nAChR antagonist MLA. This argument is further supported by the lack of response to nicotine of primary cultures from embryos of...
α4KO mice, whereas significant response was seen with BDNF, suggesting the presence of a normal signaling to neurotrophic stimuli. The lack of response to nicotine was interpreted as attributable to the absence of heteromeric α4* nAChR, the most commonly expressed nAChR in mesencephalic dopaminergic neurons (Champtiaux et al., 2003; Marubio et al., 2003) since early embryonic stages (Zoli et al., 1995). Converging findings indicate that the α4β2* nAChR participates to the control of DAergic neuron firing in the VTA and of DA release from DAergic terminals in ventral striatum (Picciotto et al., 1998; Wonnacott et al., 2000). These α4β2* nAChR regulatory effects on the mesencephalic DA system are critically involved in mediating the reinforcing properties of nicotine (Picciotto et al., 1998; Marubio et al., 2003; Changeux, 2010), evidence supported by the effects of the α4β2* nAChR partial agonist varenicline in humans and mice (Rollema et al., 2009; Reperant et al., 2010). A role of α4β2* nAChR in PD was recently suggested (Mudo et al., 2007; Quik et al., 2012). For example, varenicline reduced L-3,4-dihydroxyphenylalanine (L-DOPA)–induced abnormal involuntary movements in rats with partial striatal dopamine lesion in a model of PD (Huang et al., 2011). However, because of the higher response obtained with the 10 μM nicotine dose, with respect to the 1 μM dose, we cannot exclude the involvement of receptors other than high affinity non-α7 receptors (Jensen et al., 2005).

The morphologic changes produced by nicotine in primary cultures of mesencephalic neurons resembled those of amphetamine and cocaine (Collo et al., 2008, 2012). In these
studies, we proposed that the high extracellular DA levels produced by amphetamine and cocaine were involved in structural plasticity by activating D3 autoreceptors that are expressed in all TH-positive neurons of the mesencephalon (Diaz et al., 2000). Indeed, we showed that psychostimulant effects were blocked by a low dose of D3R antagonist SB-277011-A and did not occur in cultures from D3KO mice. Structural plasticity was produced by D3R-preferential agonists, such as 7-OH-DPAT, quinpirole, and ropinirole, all anti-Parkinsonian agents capable of driving regeneration of mesencephalic DAergic neurons after damage in vivo (Van Kampen and Eckman, 2006; Joyce and Millan, 2007).

In the present article, we propose that the activation of the D3 autoreceptors was also critical for generating nicotine-dependent structural plasticity and that these effects were possibly mediated by DA released by nicotine. Accordingly, nicotine-elicited somatodendritic release of DA in VTA was described in vitro and in vivo (Rahman et al., 2004; Kleijn et al., 2011), and preliminary findings using high-performance liquid chromatography measurements indicated that DA levels were increased by nicotine in the culture media of mesencephalic neurons (Collo, unpublished data). This hypothesis is indirectly supported by the evidence that nicotine-induced structural plasticity was completely prevented by the D3R-preferential antagonist SB-277011-A and was absent in mesencephalic cultures prepared from D3KO embryos, whereas BDNF was still effective. Of note, this interpretation is compatible with the well-established role of BDNF in controlling D3 receptor expression (Le Foll et al., 2005) and suggests a reciprocal positive-feedback relationship in generating neurotrophic effects. Receptor-receptor interaction between D3R and α4β2* nAChR could also occur, as suggested by the recently described D3R synergistic interaction with D1R (Fiorentini et al., 2008) and the proposed dimerization between non-α7* nAChR and D2 autoreceptors in striatal dopaminergic terminals (Quarta et al., 2007). However, it is possible that D3R IR expressed in other neurons of SN and VTA that do not contain DA could mediate some of these effects by engaging other neurotransmitters (e.g., glutamate) (Sokoloff et al., 2013).

Similar effects were also observed in vivo by exposing mouse embryos to nicotine during the late phase of pregnancy. We observed that nicotine increased the soma size of DAergic neurons of both VTA and SN in newborn wild-type mice. The same treatment did not produce any effect in the D3KO offspring. These results were in line with those obtained after prenatal exposure to cocaine (Collo et al., 2012), suggesting that some commonalities between nicotine and cocaine in generating structural plasticity of DAergic neurons can be related to the activation of D3R. Incidentally, prenatal exposure to nicotine and cocaine in human and rodents was associated with long-lasting postnatal neurobiological and behavioral effects (Crozatier et al., 2003; Bublitz and Stroud, 2012).

The intracellular pathways that drive the effects of nicotine on dendritic growth and soma expansion in DAergic neurons were investigated in primary mesencephalic cell cultures with use of Western blot and dual-staining immunofluorescence to localize phosphorylation events in TH-IR-positive profiles. Exposure to nicotine induced phosphorylation of ERK and of Akt within 1–2 minutes, suggesting a rapid triggering of two of the main signaling pathways involved in dendritic growth and structural plasticity (Alonso et al., 2004; Jaworski et al., 2005; Kumar et al., 2005; Scheidemn and Host, 2005). Both MEK-ERK and PI3K-Akt-mTOR pathways are known to be activated by BDNF via Ras acting as common activator (McAllister et al., 1999). Of interest, transactivation between IGF1 and D3R was described in transfected CHO cells, suggesting a possible highjacking of neurotrophin intracellular signaling (Mannoury la Cour et al., 2011). Previously, using heterologous transfection of D3R, Cussac et al. (1999) and, later, Beom et al. (2004) showed that D3Rs phosphorylate both ERK and PI3K-Akt pathways by engaging PI3K. This mechanism was recently found in DAergic neurons with use of direct and indirect DAergic agonists (Collo et al., 2008, 2012). In the present work, we showed that pretreatments with either the PI3K inhibitor LY294002 or the D3R antagonist SB-277011-A completely blocked ERK and Akt phosphorylation induced by nicotine. The effects of nicotine were not observed in mesencephalic neurons obtained from D3KO mice, further supporting a key role of D3R activation as mediator of nicotine effect. Furthermore, for the first time to our knowledge, we provide evidence that in DAergic neurons the activation of both pathways is required to trigger the phosphorylation of p70S6K, preferred substrate of mTORC1 involved in ribosomal biogenesis and protein translation (Jefferys et al., 1997; Kumar et al., 2005). The peak time of p70S6K phosphorylation followed that of ERK and Akt, supporting its downstream position in the signaling cascade. Confocal microscopy showed that nicotine-elicited p-p70S6K was present in the soma and in micro-domains of the dendrites of DA neurons that do not contain TH-IR. Phosphorylation of p70S6K was prevented by pretreatments with the selective inhibitor of mTORC1 rapamycin (Jefferys et al., 1997; Jaworski et al., 2005). These findings are in line with the early observation of dendritic micro-domain activation of p70S6K induced by N-methyl-d-aspartate in hippocampal neurons (Camilla et al., 2003). The present data strongly support the hypothesis that the observed nicotine-elicited activation of MEK-ERK and PI3K-Akt-mTOR pathways mediates structural plasticity, because rapamycin, the PI3K inhibitor LY294002, or the MEK inhibitor PD98059 blocked nicotine-induced dendrite growth and soma size increase.

In conclusion, although the relevance of the present observations to the influence of nicotine on dopaminergic pathways and cellular signals in adult neurons remains to be confirmed, they suggest a crucial role for D3R and Akt-mTOR signaling in the expression of nicotine-induced structural plasticity in mesencephalic dopaminergic neurons. As such, they provide a template for further analysis of the role of nicotinic and dopaminergic mechanisms in addiction on the one hand (mesolimbic dopaminergic neurons) and in neuroprotection and motor behavior on the other (nigrostriatal pathways). Because recent positron emission tomography findings indicate that D3R are particularly enriched in human SN and VTA (Searle et al., 2010), our findings may suggest novel strategies for the treatment of both addiction and PD.

Acknowledgments

The authors thank Marzia Melotti for technical support and Cecilia Gotti for the gifts of mecamylamine, dihydro-β-erythroidine, and methyllycaconitine.


Address correspondence to: Ginetta Collo, Department of Molecular and Translational Medicine, and Woman Health Center-Camillo Golgi Foundation, University of Brescia, Viale Europa 11, 25123 Brescia, Italy. E-mail: collo@med.unibs.it